Bloomberg the Company & Products

Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last €34.25 EUR
Change Today +0.08 / 0.23%
Volume 0.0
MRKA On Other Exchanges
As of 6:03 AM 04/24/15 All times are local (Market data is delayed by at least 15 minutes).

merck kgaa-unsponsored adr (MRKA) Snapshot

Previous Close
Day High
Day Low
52 Week High
04/13/15 - €37.40
52 Week Low
07/1/14 - €10.28
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield

Related News

No related news articles were found.

merck kgaa-unsponsored adr (MRKA) Related Businessweek News

No Related Businessweek News Found

merck kgaa-unsponsored adr (MRKA) Details

Merck Kommanditgesellschaft auf Aktien discovers, develops, manufactures, and markets pharmaceutical and chemical products worldwide. The company provides pharmaceutical and biological prescription drugs to treat cancer, multiple sclerosis, infertility, growth disorders, and cardiovascular and metabolic diseases; fertility drugs for every stage of the reproductive cycle; hypoallergenic products for specific immunotherapy and diagnosis of type 1 allergies; and biosimilars focusing on oncology and inflammatory disorders. It also manufactures and markets over-the-counter pharmaceuticals to address mobility, women’s and children’s health, cough and cold, and everyday health protection under the Neurobion, Bion, Seven Seas, Nasivin, Femibion, Dolo-Neurobion, Floratil, Sangobion, Vigantoletten, Apaisyl, and Kytta brand names. In addition, the company offers life science tools and technologies for use in the research, development, and manufacture of biotechnological and pharmaceutical drug therapies, as well as in research and application laboratories. Further, it provides specialty chemicals that are used in various end products, including liquid crystals for displays; LED materials for lighting, as well as organic light-emitting diode materials for lighting and displays; functional materials for solar panels and energy solutions; effect pigments, as well as active ingredients and fillers for cosmetics, food, and pharmaceutical products; pigments and functional materials for coatings, printing, and plastics; and specialty chemical materials for the electronics industry. The company has a strategic alliance with Pfizer Inc. to develop and commercialize active ingredients in immuno-oncology; and strategic immuno-oncology collaboration with MorphoSys to discover and develop therapeutic antibodies against immune checkpoints. Merck Kommanditgesellschaft auf Aktien was founded in 1668 and is headquartered in Darmstadt, Germany. Merck KGaA is a subsidiary of E. Merck KG.

39,639 Employees
Last Reported Date: 03/3/15
Founded in 1668

merck kgaa-unsponsored adr (MRKA) Top Compensated Officers

Chairman of Executive Board and Chief Executi...
Total Annual Compensation: €6.6M
Group Chief Financial Officer and Member of E...
Total Annual Compensation: €1.2M
Chief Executive Officer of Life Science & Per...
Total Annual Compensation: €4.7M
Vice Chairman of Executive Board and Deputy C...
Total Annual Compensation: €6.0M
Head of Group Human Resources, General Partne...
Total Annual Compensation: €4.0M
Compensation as of Fiscal Year 2014.

merck kgaa-unsponsored adr (MRKA) Key Developments

Merck KGaA, Darmstadt, and Pfizer Inc Announce Initiation and First Patient Treatment in the International Phase III Study to Assess Efficacy and Safety of Investigational Cancer Immunotherapy Avelumab

Merck KGaA, Darmstadt, and Pfizer Inc. announced the initiation and first patient treated in the international Phase III study (EMR 100070-004) designed to assess the efficacy and safety of the investigational cancer immunotherapy avelumab (MSB0010718C), compared with docetaxel, in patients with stage IIIb/IV non-small cell lung cancer (NSCLC) who have experienced disease progression after receiving a prior platinum-containing doublet therapy. The Phase III study is an open-label, multicenter, 1:1 randomized clinical trial where patients with stage IIIb/IV NSCLC will receive either avelumab or docetaxel, regardless of PD-L1 status. Approximately 650 patients will participate across 290 sites in more than 30 countries in North America, South America, Asia, Africa and Europe. In North America, clinical trials on behalf of Merck KGaA, Darmstadt, Germany, will be conducted by EMD Serono, the company’s US and Canadian biopharmaceutical businesses. The study is part of the JAVELIN clinical trial program for avelumab. The primary endpoint of the study is overall survival (OS) in patients with programmed death-ligand 1 positive (PD-L1+) stage IIIb/IV NSCLC who have experienced disease progression after receiving a prior platinum-containing doublet therapy. Secondary endpoints will be assessed across the entire study population regardless of PD-L1 status and include OS; overall response rate (ORR); progression-free survival (PFS); and patient-reported outcomes. The JAVELIN clinical trial program also includes an international Phase II trial to investigate avelumab in patients with metastatic Merkel cell carcinoma; an international Phase I trial to investigate avelumab in patients with metastatic or locally advanced solid tumors, and a Phase I trial to investigate avelumab in Japanese patients with metastatic or locally advanced solid tumors with an expansion part in Asian patients with gastric cancer. The Phase I program for avelumab includes more than 840 patients treated across multiple tumor types, including NSCLC, breast cancer, gastric cancer, ovarian cancer, bladder cancer, melanoma and mesothelioma.

Merck KGaA Confirms Earnings Guidance for the Full Year of Fiscal 2015

Merck KGaA confirmed earnings guidance for the full year of fiscal 2015. For the year, the company confirmed its cautiously optimistic full-year guidance for slight sales growth and stable or slightly higher core earnings in 2015. However, if the USD 17 billion (EUR 15.7 billion) purchase of US life science company Sigma-Aldrich Corp. is completed by mid-2015 as planned, growth will be higher. In this case, net sales should grow at a double-digit percentage rate, while earnings before interest, tax, depreciation and amortization (EBITDA) are expected to increase sharply.

Merck Appoints Udit Batra to Head Combined Life Science Business of Merck Millipore and Sigma-Aldrich

Merck announced that Udit Batra, currently CEO and President of Merck Millipore, has been appointed to lead the combined life science business of Merck Millipore and Sigma-Aldrich once the acquisition of Sigma-Aldrich has been successfully completed. The planned $17 billion transaction remains subject to customary closing conditions and regulatory approvals, which the company expects to have completed in mid-2015. Until then, Merck Millipore and Sigma-Aldrich will continue to operate as separate companies with Udit Batra and Rakesh Sachdev, President and CEO of Sigma-Aldrich, running both organizations independently. Rakesh Sachdev will serve in an advisory capacity, as needed, to ensure a smooth transition. Udit Batra, 44, has served as CEO and President of Merck's life science business Merck Millipore since March 2014. He joined Merck in 2011 to head the Group's Consumer Health business. Prior to that, Udit Batra worked at Novartis Vaccines and Diagnostics, where he was head of Global Public Health and Market Access. He served in a range of executive management positions at Novartis, including global Head of Corporate Strategy and Country President for the Pharma Business in Australia.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
MRKA:GR €34.25 EUR +0.08

MRKA Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Akzo Nobel NV €70.67 EUR -0.73
Johnson Matthey PLC 3,412 GBp +7.00
Koninklijke DSM NV €51.97 EUR -0.03
Solvay SA €134.65 EUR +0.05
Yara International ASA 404.00 NOK -9.50
View Industry Companies

Industry Analysis


Industry Average

Valuation MRKA Industry Range
Price/Earnings 35.5x
Price/Sales 3.6x
Price/Book 3.5x
Price/Cash Flow 10.6x
TEV/Sales 0.1x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact MERCK KGAA-UNSPONSORED ADR, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at